| Name | Title | Contact Details |
|---|---|---|
Nallakkan Arvindan |
Chief Technology Officer | Profile |
Respira Therapeutics, Inc., founded in 2010 with offices in Albuquerque, New Mexico, is a development stage inhaled pharmaceutical development company focused on commercializing its "best in class", high efficiency AOS-DPI, dry powder inhaler (DPI) drug delivery technology to deliver RT234, a proprietary inhaled formulation of an off patent oral drug via the lung to treatment of multiple orphan indications in the fields of pulmonary hypertension and other diseases. Investors in Respira include Cottonwood Technology Fund and Sun Mountain Capital and individual investors. To date Respira has performed extensive testing demonstrating its advanced AOS-DPI prototypes can deliver 2-3X more drug to the lung than commercially available DPI technologies. Respira is planning proof of concept clinical trials of an inhaled formulation of RT234 in pulmonary arterial hypertension patients in the near future.
Cytovia is dedicated to the development of transformational cancer immunotherapies, addressing several of the most challenging unmet medical needs including the prevention of cancer relapse and metastasis. Cytovia focuses on Natural Killer (NK) cell biology and applies precision medicine tools to develop the right therapy for the right patient at the right stage of the disease. Cytovia has secured access to multiple advanced technologies, including allogeneic cell therapy, multispecific antibodies, and cytokines. Cytovia establishes development partnerships to accelerate time-to-market and commercialization alliances in order to optimize rapid adoption of its novel immunotherapies.
CLS Health is a multi-specialty medical group with 90+ providers providing comprehensive inpatient & outpatient care in Houston, TX
Critical Outcome Technologies Inc. is a London, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Macrocure Ltd. is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Our novel approach is to treat and close chronic and other hard-to-heal wounds by injecting the human body`s own wound healing and regenerative components directly into the wound itself.